Seamless

Seamless Therapeutics is a biotechnology company. The company is applying its proprietary technology to develop a broad pipeline of disease-modifying candidates across a wide range of indications, aiming to expand the therapeutic potential of gene editing. The platform has successfully reprogrammed site-specific recombinases to target any given sequence and perform a series of specific modifications, including inversions, excisions, swaps, and insertions of DNA fragments ranging from small to large. Recombinases are a class of enzymes that have been widely used in scientific research for decades to precisely modify the genomes of model organisms, but due to their limited programmability for acting on new target sites, they have not been usable as therapeutics until now.